KR102399290B1 - 10-하이드록시-2-데센산을 포함하는 방법 및 조성물 - Google Patents

10-하이드록시-2-데센산을 포함하는 방법 및 조성물 Download PDF

Info

Publication number
KR102399290B1
KR102399290B1 KR1020167034149A KR20167034149A KR102399290B1 KR 102399290 B1 KR102399290 B1 KR 102399290B1 KR 1020167034149 A KR1020167034149 A KR 1020167034149A KR 20167034149 A KR20167034149 A KR 20167034149A KR 102399290 B1 KR102399290 B1 KR 102399290B1
Authority
KR
South Korea
Prior art keywords
day
amount
acid
hydroxy
pufa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167034149A
Other languages
English (en)
Korean (ko)
Other versions
KR20170003637A (ko
Inventor
마이클 와이저
크리스토퍼 버트
Original Assignee
디에스엠 아이피 어셋츠 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디에스엠 아이피 어셋츠 비.브이. filed Critical 디에스엠 아이피 어셋츠 비.브이.
Publication of KR20170003637A publication Critical patent/KR20170003637A/ko
Application granted granted Critical
Publication of KR102399290B1 publication Critical patent/KR102399290B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020167034149A 2014-05-08 2015-05-07 10-하이드록시-2-데센산을 포함하는 방법 및 조성물 Expired - Fee Related KR102399290B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990283P 2014-05-08 2014-05-08
US61/990,283 2014-05-08
PCT/US2015/029790 WO2015171960A1 (en) 2014-05-08 2015-05-07 Methods and compositions comprising 10-hydroxy-2-decenoic acid

Publications (2)

Publication Number Publication Date
KR20170003637A KR20170003637A (ko) 2017-01-09
KR102399290B1 true KR102399290B1 (ko) 2022-05-17

Family

ID=54393026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167034149A Expired - Fee Related KR102399290B1 (ko) 2014-05-08 2015-05-07 10-하이드록시-2-데센산을 포함하는 방법 및 조성물

Country Status (8)

Country Link
US (1) US10004711B2 (https=)
EP (1) EP3139741A4 (https=)
JP (1) JP6819957B2 (https=)
KR (1) KR102399290B1 (https=)
CN (1) CN106470547B (https=)
BR (1) BR112016026143A2 (https=)
TW (1) TWI743022B (https=)
WO (1) WO2015171960A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016364670B2 (en) * 2015-12-04 2022-08-04 Wah Chin Boon Methods of treating or alleviating mental disorders and associated symptoms
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
CN108310026A (zh) * 2018-04-28 2018-07-24 宁夏医科大学 月见草油在改善多囊卵巢综合征慢性炎症方面的应用
JP7240714B2 (ja) * 2019-01-24 2023-03-16 株式会社山田養蜂場本社 γヒドロキシ酪酸受容体結合剤
CN110916088A (zh) * 2019-11-04 2020-03-27 齐鲁工业大学 一种适合炎性肠病人群的全营养特医食品及制备方法
CN112094790B (zh) * 2020-11-17 2021-03-02 河北一然生物科技有限公司 一种调节肠道菌群的植物乳杆菌lp45活菌制剂及应用
TWI793922B (zh) * 2021-12-14 2023-02-21 彥臣生技藥品股份有限公司 一種用於提升認知能力之組合物及其用途
CN116570582A (zh) * 2023-05-19 2023-08-11 中国药科大学 10-羟基癸烯酸在制备重度抑郁治疗药物中的应用
CN119745857A (zh) * 2024-12-02 2025-04-04 温州医科大学 10-羟基-2-癸烯酸在药物制备中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1033843A (en) 1964-05-26 1966-06-22 Eustace Cecil Barton Wright Pharmaceutical composition for treating thermatoid arthritis
GB1145623A (en) 1966-03-09 1969-03-19 Eustace Cecil Barton Wright Pharmaceutical composition
JPH10114652A (ja) 1996-10-15 1998-05-06 Dokutaazu Kosumeteikusu:Kk 津液改善剤及びそれを含有する経口投与用組成物
AU7222598A (en) 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
FR2773484B1 (fr) * 1998-01-09 2001-03-30 Pierre Moreau Nouvelles compositions a effet synergique entre micronutriments et substances d'origine vivante
DE19844022C1 (de) 1998-09-25 2000-05-25 Sherif Sabry Ragab Mekkawi Verwendung von eisenbindenden Glycoproteinen und/oder 10-Hydroxy-2-decensäure in Verbindung mit Thymochinon zur Behandlung von AIDS
DE60135333D1 (de) * 2000-06-01 2008-09-25 Jbs United Inc Tiernahrung sowie verfahren
FR2825919B1 (fr) 2001-06-14 2004-06-11 Oreal Utilisation d'au moins un derive de l'acide 10-hydroxy-2- decenoique dans des compositions destinees a traiter les signes cutanes du vieillissement
FR2829491B1 (fr) 2001-09-12 2005-09-30 Diverchim Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
NZ535549A (en) * 2002-03-08 2006-02-24 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
JP4384981B2 (ja) 2002-09-06 2009-12-16 林原 健 精製ローヤルゼリー
JP2004131407A (ja) * 2002-10-09 2004-04-30 Yamada Bee Farm ローヤルゼリー又はその水溶性画分を有効成分とする抗うつ性組成物
JP4657778B2 (ja) 2004-03-30 2011-03-23 曽田香料株式会社 アラキドン酸代謝抑制剤
JP4727939B2 (ja) 2004-03-31 2011-07-20 アピ株式会社 低アレルゲン化ローヤルゼリーの製造方法
JP4579620B2 (ja) * 2004-08-25 2010-11-10 アピ株式会社 エストロゲン様作用剤及びその製造方法、並びに骨粗しょう症予防剤及び骨粗しょう症治療剤
CN1836671A (zh) 2005-03-21 2006-09-27 通化盛和药业股份有限公司 一种中药软胶囊及其制备方法和质量控制方法
FR2892410B1 (fr) 2005-10-21 2010-10-15 Fabre Pierre Dermo Cosmetique Nouveaux hydro-acides gras insatures et leur utilisation dermo cosmetologique
AU2006330669A1 (en) * 2005-12-20 2007-07-05 Novozymes Biologicals, Inc. Surfactants systems for surface cleaning
EP1976501B1 (en) * 2005-12-29 2014-10-22 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating inflammatory bowel disease
WO2007130581A2 (en) * 2006-05-04 2007-11-15 Hardwicke Susan B Compositions and methods for psychiatric conditions and cognition enhancement
JP4749366B2 (ja) 2007-03-23 2011-08-17 株式会社山田養蜂場本社 ローヤルゼリー粉末からなる錠剤およびその製造方法
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
JP2009274961A (ja) 2008-05-12 2009-11-26 Api Co Ltd 吸収促進剤
CN101801398A (zh) * 2008-06-17 2010-08-11 日本蜂王浆株式会社 认知障碍改善剂
JP2010111646A (ja) * 2008-11-07 2010-05-20 Hayashibara Biochem Lab Inc 潰瘍性大腸炎治療剤
WO2013003689A2 (en) 2011-06-30 2013-01-03 Nitromega Corp. Compositions containing nitro fatty acids
JP2010260833A (ja) * 2009-05-11 2010-11-18 Daicho Kikaku:Kk 抗自己免疫疾患剤
CN101570482B (zh) 2009-06-09 2012-12-26 李应阳 由ω-氯辛醇合成蜂王酸的方法
JP2012031153A (ja) * 2010-06-29 2012-02-16 Takara Bio Inc 脂肪燃焼促進剤
JP5770453B2 (ja) * 2010-11-22 2015-08-26 八幡物産株式会社 ローヤルゼリー含有組成物及びソフトカプセル
JP5923699B2 (ja) 2011-03-30 2016-05-25 アピ株式会社 老化防止剤
CN102408395B (zh) 2011-10-24 2014-04-02 广西师范大学 新的哌嗪和高哌嗪类衍生物及其制备方法和应用
WO2013066152A1 (en) * 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013134482A1 (en) * 2012-03-07 2013-09-12 Children's Medical Center Corporation Methods for enhancing, improving, or increasing fertility or reproductive function
CA2867438A1 (en) * 2012-03-14 2013-09-19 Abbott Laboratories Nutritional compositions including rrr-alpha tocopherol and polyunsaturated fatty acids
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biomed. Research, 28(5), 261-266, 2007.*
Innate Immunity, 18(3), 429-327, 2012.*
J. Argic. Food Chem., 59, 2627-2635, 2011.
Scientific Papers, Animal Science and Biotechnologies. 44(2), 108-118, 2011.*

Also Published As

Publication number Publication date
JP6819957B2 (ja) 2021-01-27
TW201622717A (zh) 2016-07-01
EP3139741A1 (en) 2017-03-15
US10004711B2 (en) 2018-06-26
CN106470547B (zh) 2020-10-09
US20170181995A1 (en) 2017-06-29
JP2017514874A (ja) 2017-06-08
TWI743022B (zh) 2021-10-21
CN106470547A (zh) 2017-03-01
BR112016026143A2 (pt) 2018-08-07
WO2015171960A1 (en) 2015-11-12
EP3139741A4 (en) 2017-11-29
KR20170003637A (ko) 2017-01-09

Similar Documents

Publication Publication Date Title
KR102399290B1 (ko) 10-하이드록시-2-데센산을 포함하는 방법 및 조성물
Romanova et al. Evaluation of the content of polyunsaturated fatty acids in artemia at different stages of ontogenesis
Kapoor et al. Dietary polyunsaturated fatty acids (PUFAs): Uses and potential health benefits
Al-Khalaifah Modulatory effect of dietary polyunsaturated fatty acids on immunity, represented by phagocytic activity
Wu et al. Curcumin boosts DHA in the brain: Implications for the prevention of anxiety disorders
Crupi et al. n-3 fatty acids: role in neurogenesis and neuroplasticity
Fang et al. Effects of organic carbon sources on cell growth and eicosapentaenoic acid content of Nannochloropsis sp.
Pottel et al. Omega-3 fatty acids: physiology, biological sources and potential applications in supportive cancer care
JP2014195460A (ja) 乳幼児用調合乳におけるＤＰＡ（ｎ−６）油の使用
EA035287B1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
Qiu et al. Biosafety evaluation of Nannochloropsis oculata and Schizochytrium sp. oils as novel human milk fat substitutes
Vidyashankar et al. Evaluation of microalgae as vegetarian source of dietary polyunsaturated fatty acids under autotrophic growth conditions
US20200009099A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
Calder Marine omega-3 fatty acids and inflammation
Alva et al. Bridging the Gap: Investigating the Interplay of Polyunsaturated Fatty Acids and Osteoporosis
AL-KHALAIFAH et al. Fatty Acids and Immune Function
Jeong et al. Lipid and fatty acid composition in Nannochloropsis oculata cultured in varying salinities
Sartaj et al. Production of Omega‐3 and Omega‐6 PUFA from Food Crops and Fishes
Al-Khalaifah Lipids as Main Constitutes of Biological Cells
Abuajamieh et al. Dietary Flaxseed Supplementation to Enhance Productivity and Omega-3 Enrichment in Laying Hens.
Ouyang et al. Resources and bioactivities of polyunsaturated fatty acids
Эргашева et al. OMEGA-3 AND BIOCHEMICAL PROCESSES OF INFLAMMATION IN THE BODY
MUANGKEOW Effect of feeding soybean and palm blended oil on laying performance and egg quality
Weng Immunomodulation by dietary lipids: Soybean oil, menhaden fish oil, chicken fat, and hydrogenated soybean oil in Japanese quail (Coturnix coturnix japonica) and bobwhite quail (Colinus virginianus)
Volker Fat manipulation in the treatment of rheumatoid arthritis: a review

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250514

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250514

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250514